Allogene Therapeutics (ALLO) Depreciation and Depletion (2019 - 2024)

Allogene Therapeutics has disclosed Depreciation and Depletion across 6 years of filings, most recently posting $3.6 million for Q1 2024.

• Depreciation and Depletion for Q1 2024 came in at $3.6 million, up 1.37% year-over-year; the trailing twelve-month figure through Mar 2024 was $14.2 million (up 0.97% YoY), and the FY2023 annual result was $14.2 million, down 0.67% from the prior year.
• Depreciation and Depletion came in at $3.6 million for Q1 2024 at Allogene Therapeutics, up from $3.5 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $4.2 million in Q4 2021 to a low of $1.8 million in Q3 2020.
• The 5-year median for Depreciation and Depletion is $3.5 million (2023), against an average of $2.9 million.
• Across the five-year window, Depreciation and Depletion surged 247.98% in 2020 and dropped 27.68% in 2022, its largest moves.
• Allogene Therapeutics' Depreciation and Depletion stood at $1.8 million in 2020, then soared by 130.04% to $4.2 million in 2021, then declined by 27.68% to $3.1 million in 2022, then increased by 13.33% to $3.5 million in 2023, then rose by 2.24% to $3.6 million in 2024.
• The last three Depreciation and Depletion figures came in at $3.6 million (Q1 2024), $3.5 million (Q4 2023), and $3.6 million (Q3 2023), per Business Quant data.